ONE-WAYOngoing theme · still written in the latest filings
Iusurui (pirfenidone)’s penetration of China’s IPF market and sales expansion
A theme focused on continued revenue growth as Iusurui (pirfenidone), the company’s core pharmaceutical product, gains further penetration in China’s idiopathic pulmonary fibrosis (IPF) market.
Companies1How many companies write about this.
Threads2One company can carry more than one thread here.